drugset / Trial / NCT00190749

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749

Phase 4 Completed 130 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.

Timeline

Start
2003-10
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 5 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Comparator Risperidone Other / unclassified 2 mg Oral
Comparator Risperidone Other / unclassified 6 mg Oral